BNP Paribas Increases Stock Position in Eli Lilly and Company $LLY

BNP Paribas increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,248 shares of the company’s stock after acquiring an additional 718 shares during the quarter. Eli Lilly and Company comprises 1.1% of BNP Paribas’ holdings, making the stock its 21st biggest position. BNP Paribas’ holdings in Eli Lilly and Company were worth $40,046,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. State Street Corp increased its stake in Eli Lilly and Company by 0.6% during the 3rd quarter. State Street Corp now owns 34,726,558 shares of the company’s stock valued at $26,496,364,000 after purchasing an additional 219,590 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 4.1% in the third quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock worth $11,112,164,000 after acquiring an additional 574,229 shares during the period. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $12,976,634,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,079.96 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company’s 50-day moving average price is $959.18 and its 200-day moving average price is $1,010.74. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,149.10. The company has a market cap of $1.02 trillion, a P/E ratio of 38.36, a P/E/G ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the firm earned $3.34 earnings per share. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a report on Thursday, May 21st. Bank of America increased their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,227.00.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 data for Retevmo (selpercatinib), showing an 83% reduction in the risk of disease recurrence or death in early-stage RET fusion-positive lung cancer, a result that could support a broader label and future revenue growth. Article Title
• Positive Sentiment: The company also signed new licensing and collaboration deals with Hanmi and Haisco, extending its innovation pipeline and signaling continued deal-making momentum in Asia. Article Title
• Positive Sentiment: Camurus said Lilly exercised an option in their cardiometabolic drug collaboration, extending another pipeline partnership and adding to investor confidence in Lilly’s long-term growth strategy. Article Title
• Positive Sentiment: Market commentary remained bullish after CEO David Ricks’ remarks about Lilly’s hot product lineup, while social sentiment and analyst coverage continued to highlight the company as one of the market’s leading growth names. Article Title
• Neutral Sentiment: Some articles framed Lilly as one of the top stocks to watch, but these pieces were mostly commentary rather than new company-specific catalysts. Article Title
• Negative Sentiment: Despite the positive news, LLY has been trading lower recently, and some market attention appears to reflect profit-taking after a strong run and valuation concerns rather than a deterioration in fundamentals. Article Title
• Negative Sentiment: Competitive pressure in the GLP-1 market remains a risk, as Novo Nordisk’s oral Wegovy pill is still outperforming Lilly’s rival tablet, even though growth is slowing. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.